drugset

drugset / Trial / NCT03503266

Mass Balance Study With MT-7117

NCT03503266 ↗

Phase 1 Completed 6 enrolled Tanabe Pharma America, Inc.

NaSingle-groupOpen-labelOther

Summary

This is a single-centre, open-label, mass balance study in healthy male subjects utilising a single oral dose of \[14C\] MT 7117.

Timeline

Start: 2018-03-23
Primary completion: 2018-05-11
Completion: 2018-05-11

Publications

Ogasawara A, Ide R, Inoue S, Tsuda M, Teng R. Assessment of Potential Drug-Drug Interactions for Novel Oral Melanocortin-1 Receptor Agonist Dersimelagon. Pharmacol Res Perspect. 2025 Feb;13(1):e70069. doi: 10.1002/prp2.70069.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dersimelagon	Small molecule	—	Oral

Indications

No indication recorded.